Presenter Bio: Jason DiBona
Mr. DiBona has served as our Chief Executive Officer since May 2020. Mr. DiBona brings more than 25 years of experience in developing and executing strategies for sustainable growth. He has held leadership roles in medical and healthcare technologies, global sales operations and start-up environments and has experience working with diverse private and public sector clients in more than 120 countries. Mr. DiBona spent the majority of his career, from 1999 to 2014, at GE Healthcare, holding multiple leadership and business development roles across the global healthcare organization. After his time at GE Healthcare, from 2014 to 2018, Mr. DiBona led the sales and marketing efforts at ePreop, a start-up medical software developer, with a successful launch and exit in the role of Executive Vice President of Sales and Marketing. Prior to AeroClean, Mr. DiBona served as Senior Vice President of Global Sales Strategies for America’s largest homebuilder, Lennar Corporation. Mr. DiBona earned his Bachelor of Science degrees in Molecular Biology and Microbiology from the University of Central Florida.
Effectiveness of improving IAQ with portable air purifiers is dependent upon laboratory-based performance of the purifier and the unique environment (size, geometry) in which the purifier will operate. The recent recommendation of the Lancet Covid-19 Commission recognizes this reality and recommends that more than just laboratory testing is required to quantify device performance in the real world. Testing with active pathogens in real world settings is time consuming and expensive. Development of a convenient testing methodology which produces results accurate enough to ensure meaningful pathogen reduction data is desirable. Fine particle reduction testing using a high-performance particle detector (≥ 0.50 µm) in a large, densely populated room was compared with reduction in a smaller, medical exam room. Fine particle reduction of 61-76% was achieved in the large setting (24,000 cubic feet with 7 air purifiers) and 68-79% in the small setting (1200 cubic feet with 1 air purifier). These fine particle reduction data combined with SARS CoV-2 information and human factors estimates such as inhaled volume and breathing rate were used in the Wells Riley infectious probability model to estimate performance level. The calculated reduction in infection probability for the small setting was 63% and for the large setting 70%. These data suggest the use of fine particle arrestance testing can provide meaningful insight for the effective deployment of portable air purifiers in various settings.